Australia · Delayed Price · Currency is AUD Cambium Bio Statistics
Total Valuation
Cambium Bio has a market cap or net worth of AUD 11.07 million. The enterprise value is 10.71 million.
| Market Cap | 11.07M |
| Enterprise Value | 10.71M |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Cambium Bio has 27.33 million shares outstanding. The number of shares has increased by 164.97% in one year.
| Current Share Class | 27.33M |
| Shares Outstanding | 27.33M |
| Shares Change (YoY) | +164.97% |
| Shares Change (QoQ) | -12.20% |
| Owned by Insiders (%) | 17.64% |
| Owned by Institutions (%) | n/a |
| Float | 7.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.55 |
| PB Ratio | 4.28 |
| P/TBV Ratio | 80.35 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 16.01 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.15, with a Debt / Equity ratio of 0.16.
| Current Ratio | 1.15 |
| Quick Ratio | 1.04 |
| Debt / Equity | 0.16 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.11 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -167.57% and return on invested capital (ROIC) is -95.70%.
| Return on Equity (ROE) | -167.57% |
| Return on Assets (ROA) | -68.91% |
| Return on Invested Capital (ROIC) | -95.70% |
| Return on Capital Employed (ROCE) | -152.47% |
| Weighted Average Cost of Capital (WACC) | 3.41% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.19 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +35.00% in the last 52 weeks. The beta is -0.13, so Cambium Bio's price volatility has been lower than the market average.
| Beta (5Y) | -0.13 |
| 52-Week Price Change | +35.00% |
| 50-Day Moving Average | 0.43 |
| 200-Day Moving Average | 0.42 |
| Relative Strength Index (RSI) | 43.65 |
| Average Volume (20 Days) | 3,267 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Cambium Bio had revenue of AUD 668,792 and -3.57 million in losses. Loss per share was -0.16.
| Revenue | 668,792 |
| Gross Profit | 457,344 |
| Operating Income | -3.94M |
| Pretax Income | -3.57M |
| Net Income | -3.57M |
| EBITDA | -3.94M |
| EBIT | -3.94M |
| Loss Per Share | -0.16 |
Balance Sheet
The company has 774,313 in cash and 413,564 in debt, with a net cash position of 360,749 or 0.01 per share.
| Cash & Cash Equivalents | 774,313 |
| Total Debt | 413,564 |
| Net Cash | 360,749 |
| Net Cash Per Share | 0.01 |
| Equity (Book Value) | 2.59M |
| Book Value Per Share | 0.11 |
| Working Capital | 135,181 |
Cash Flow
In the last 12 months, operating cash flow was -3.89 million and capital expenditures -2,929, giving a free cash flow of -3.89 million.
| Operating Cash Flow | -3.89M |
| Capital Expenditures | -2,929 |
| Depreciation & Amortization | 7,523 |
| Net Borrowing | -57,252 |
| Free Cash Flow | -3.89M |
| FCF Per Share | -0.14 |
Margins
| Gross Margin | 68.38% |
| Operating Margin | -589.82% |
| Pretax Margin | -534.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cambium Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -164.97% |
| Shareholder Yield | -164.97% |
| Earnings Yield | -32.29% |
| FCF Yield | -35.17% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on July 4, 2024. It was a reverse split with a ratio of 0.01.
| Last Split Date | Jul 4, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.01 |
Scores
Cambium Bio has an Altman Z-Score of -17.88 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -17.88 |
| Piotroski F-Score | 1 |